ASP-5736 ameliorates abnormal behaviors in rat model of fragile X syndrome
Oct. 24, 2022
Researchers from Astellas Pharma Inc. presented preclinical data for the novel 5-HT5A receptor antagonist, ASP-5736, being developed for the treatment of fragile X syndrome (FXS).